Literature DB >> 23664289

[Epidemiology, management and cost of bone metastases from lung cancer].

C Decroisette1, L-M Galerneau, S Hominal, C Chouaid.   

Abstract

UNLABELLED: In lung cancer, there is a significant incidence of bone metastases with skeletal complications affecting more than 50% of patients. The systematic detection of bone metastases should be included in the initial staging of lung cancer in order to begin their management at an early stage. Treatment is either pharmacological (analgesics, zoledronic acid, anti-rank ligand) or non-pharmacological (radiotherapy, interventional radiological techniques, surgery) especially when bone metastases become symptomatic or complicated. External beam radiation, used for both analgesia and strengthening, can be combined with percutaneous and surgical treatments. Prophylactic or restorative surgery for pathological fractures should be subject to multidisciplinary discussion. Finally, the medico-economic impact of bone metastases is substantial. This is related to treatment of bone complications, which emphasises the importance of their prevention.
CONCLUSION: Bone metastases from lung cancer cause complications which impact on patients' quality of life. Their management should be by a multidisciplinary approach in view of the numerous therapeutic options.
Copyright © 2012 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23664289     DOI: 10.1016/j.rmr.2012.12.005

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

1.  Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain.

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Anna Nardelli; Teresa Pellegrino; Vittorio Simeon; Domenico Gattozzi; Francesca Maddalena; Pierpaolo Mainenti; Giovanni Storto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

2.  Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene.

Authors:  Yunxi Ji; Sheng Xie; Li Jiang; Lijian Liu; Liumei Li; Lichuan Luo; Yan Chen; Jianxuan Zhang; Lei Yu; Yaozhong Zhang; Nong Tang; Bugu Liu
Journal:  Oncol Lett       Date:  2017-08-17       Impact factor: 2.967

3.  The homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis.

Authors:  Ben Wang; Lijie Chen; Chongan Huang; Jialiang Lin; Xiangxiang Pan; Zhenxuan Shao; Sunli Hu; Xiaolei Zhang; Xiangyang Wang
Journal:  J Bone Oncol       Date:  2019-07-09       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.